Previus studies have demonstrated that mutations in KRAS can directly lead to a failure for CRC patients subjected to anti-epidermal growth factor receptor (EGFR) therapy, such as cetuximab 45, 46. The gene discussed is KRAS; the disease is colorectal carcinoma.